HymonBio will showcase many innovative molecular diagnostic products and new progress of our company in 2023 Medica! Thank you for your continued support. We hope to meet you there!
Company Profile
HymonBio focuses on the development, production, and sale of molecular diagnostic reagents in the precision medical industry, covering fields that include tumor, pathogen molecular detection, and medicine guidance.
- 11 products have obtained Chinese medical device certification
- 59 products have obtained EU CE certification
- 1 produce has obtained FDA EUA certification
- 36 patent applications
- 16 patent authoritzations
Key Technologies
- ECS technology improves extraction efficency of low-concentration cell-free nucleic acid by up tp 90%
- MOLOCK technology solves interference of wild-type genes and amplifies mutant genes, removing 99% of background noise
- One-step nucleic acid extraction technology allows 3-minute nucleic acid extractions, with 30-minute qPCR sample-to-result
- DIDC dual quality control system montiors sampling to detection
- Freeze-dried PCR reagents maintains stable performance and eliminates the need for cold-chain transportation, reducing logistics and storage costs
Rich Product Line
Some kits include: colorectal cancer screening kit, gastric cancer screening kit, bladder cancer screening kit, respiratory tract multiplex screening kit, urogenital multiplex screening kit, etc.
Post time: Sep-01-2023